These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 33811017)
1. Metastatic or suspected metastatic cancer in patients 90 years of age or older: A single-institution, multi-site study. Almodallal Y; Cook KD; Mannion S; Hanna M; Martin NA; Nguyen PL; Jatoi A J Geriatr Oncol; 2021 Nov; 12(8):1220-1224. PubMed ID: 33811017 [TBL] [Abstract][Full Text] [Related]
2. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136 [TBL] [Abstract][Full Text] [Related]
3. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963 [TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN; Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173 [TBL] [Abstract][Full Text] [Related]
5. Understanding "Patient refuses" among 90+ year old patients with cancer or presumed cancer. Wieland J; Almodallal Y; Martin NA; Mannion S; Nguyen P; Jatoi A J Geriatr Oncol; 2022 Jun; 13(5):715-719. PubMed ID: 35232696 [TBL] [Abstract][Full Text] [Related]
6. Cancer in nonagenarians: profile, treatments and outcomes. Extermann M; Crane EJ; Boulware D Crit Rev Oncol Hematol; 2010 Aug; 75(2):160-4. PubMed ID: 20656211 [TBL] [Abstract][Full Text] [Related]
7. Radiotherapy in nonagenarian patients: A 20-year retrospective analysis in a single ternary centre. Katano A; Yamashita H J Med Imaging Radiat Oncol; 2024 Feb; 68(1):103-109. PubMed ID: 37964705 [TBL] [Abstract][Full Text] [Related]
8. Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. Reddy N; Yu J; Fakih MG Clin Colorectal Cancer; 2007 Jan; 6(5):362-6. PubMed ID: 17311701 [TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514 [TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595 [TBL] [Abstract][Full Text] [Related]
11. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J; Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005 [TBL] [Abstract][Full Text] [Related]
12. Colonoscopy in Nonagenarians Is Safe and May Be Associated with Clinical Benefit. Shafrir A; Koslowsky B; Wengrower D; Goldin E; Livovsky DM J Am Geriatr Soc; 2019 Jun; 67(6):1158-1163. PubMed ID: 30801669 [TBL] [Abstract][Full Text] [Related]
13. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Meulenbeld HJ; van Steenbergen LN; Janssen-Heijnen ML; Lemmens VE; Creemers GJ Ann Oncol; 2008 Sep; 19(9):1600-4. PubMed ID: 18467312 [TBL] [Abstract][Full Text] [Related]
14. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer. Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967 [TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614 [TBL] [Abstract][Full Text] [Related]
17. High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer. Reynolds J; Chamberland-Tremblay A; Herrington JD; Munoz Maldonado Y; Wong L J Oncol Pharm Pract; 2017 Apr; 23(3):173-178. PubMed ID: 26786027 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J; Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601 [TBL] [Abstract][Full Text] [Related]
19. Sarcoma of the prostate: a single institutional review. Janet NL; May AW; Akins RS Am J Clin Oncol; 2009 Feb; 32(1):27-9. PubMed ID: 19194120 [TBL] [Abstract][Full Text] [Related]
20. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]